Batterjee has been in his current position since joining the company in 2014. Batterjee Pharma manufactures and markets generic pharmaceutical products and also serves as a contract development and manufacturing organization (CDMO). In the past year, Batterjee Pharma signed seven localization agreements and started production for over 30 products. Its SuperGrow initiative led to 38% growth in CDMO, 37% in the local market, and 53% in exports. Batterjee is also a cofounder of KaryoBio and AUMET.